nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—Flupirtine—ADRA2A—attention deficit hyperactivity disorder	0.0714	1	CrCbGaD
Ezogabine—KCNQ5—forebrain—attention deficit hyperactivity disorder	0.0457	0.0976	CbGeAlD
Ezogabine—KCNQ3—forebrain—attention deficit hyperactivity disorder	0.0367	0.0783	CbGeAlD
Ezogabine—KCNQ3—Interaction between L1 and Ankyrins—ANK3—attention deficit hyperactivity disorder	0.0367	0.0797	CbGpPWpGaD
Ezogabine—KCNQ2—Interaction between L1 and Ankyrins—ANK3—attention deficit hyperactivity disorder	0.0367	0.0797	CbGpPWpGaD
Ezogabine—KCNQ2—forebrain—attention deficit hyperactivity disorder	0.0338	0.0721	CbGeAlD
Ezogabine—KCNQ3—cardiovascular system—attention deficit hyperactivity disorder	0.031	0.0662	CbGeAlD
Ezogabine—KCNQ5—midbrain—attention deficit hyperactivity disorder	0.0302	0.0644	CbGeAlD
Ezogabine—KCNQ5—nervous system—attention deficit hyperactivity disorder	0.0248	0.053	CbGeAlD
Ezogabine—KCNQ3—midbrain—attention deficit hyperactivity disorder	0.0242	0.0517	CbGeAlD
Ezogabine—KCNQ4—cerebellum—attention deficit hyperactivity disorder	0.024	0.0512	CbGeAlD
Ezogabine—KCNQ5—central nervous system—attention deficit hyperactivity disorder	0.0239	0.051	CbGeAlD
Ezogabine—KCNQ3—nervous system—attention deficit hyperactivity disorder	0.0199	0.0425	CbGeAlD
Ezogabine—KCNQ4—brain—attention deficit hyperactivity disorder	0.0195	0.0416	CbGeAlD
Ezogabine—KCNQ3—central nervous system—attention deficit hyperactivity disorder	0.0192	0.0409	CbGeAlD
Ezogabine—KCNQ5—brain—attention deficit hyperactivity disorder	0.019	0.0405	CbGeAlD
Ezogabine—KCNQ3—cerebellum—attention deficit hyperactivity disorder	0.0187	0.04	CbGeAlD
Ezogabine—KCNQ2—nervous system—attention deficit hyperactivity disorder	0.0183	0.0391	CbGeAlD
Ezogabine—KCNQ2—central nervous system—attention deficit hyperactivity disorder	0.0177	0.0377	CbGeAlD
Ezogabine—KCNQ2—cerebellum—attention deficit hyperactivity disorder	0.0173	0.0368	CbGeAlD
Ezogabine—KCNQ5—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.0153	0.0332	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.0153	0.0332	CbGpPWpGaD
Ezogabine—KCNQ3—brain—attention deficit hyperactivity disorder	0.0152	0.0325	CbGeAlD
Ezogabine—KCNQ2—L1CAM interactions—ANK3—attention deficit hyperactivity disorder	0.0141	0.0306	CbGpPWpGaD
Ezogabine—KCNQ3—L1CAM interactions—ANK3—attention deficit hyperactivity disorder	0.0141	0.0306	CbGpPWpGaD
Ezogabine—KCNQ2—brain—attention deficit hyperactivity disorder	0.014	0.0299	CbGeAlD
Ezogabine—UGT1A3—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.0123	0.0267	CbGpPWpGaD
Ezogabine—CYP2A6—cerebellum—attention deficit hyperactivity disorder	0.00857	0.0183	CbGeAlD
Ezogabine—UGT1A1—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00848	0.0185	CbGpPWpGaD
Ezogabine—UGT1A9—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00848	0.0185	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00825	0.0179	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00825	0.0179	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00782	0.017	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00782	0.017	CbGpPWpGaD
Ezogabine—CYP2A6—brain—attention deficit hyperactivity disorder	0.00696	0.0149	CbGeAlD
Ezogabine—NAT2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00685	0.0149	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00673	0.0146	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00673	0.0146	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—DPYD—attention deficit hyperactivity disorder	0.00654	0.0142	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00625	0.0136	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00625	0.0136	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00557	0.0121	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00557	0.0121	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00532	0.0116	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00532	0.0116	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00474	0.0103	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00474	0.0103	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.0047	0.0102	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.0047	0.0102	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00422	0.00918	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00422	0.00918	CbGpPWpGaD
Ezogabine—UGT1A4—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00415	0.00903	CbGpPWpGaD
Ezogabine—NAT2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00401	0.00871	CbGpPWpGaD
Ezogabine—NAT2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00398	0.00865	CbGpPWpGaD
Ezogabine—NAT2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00395	0.00859	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.0038	0.00825	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.0038	0.00825	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.00375	0.00815	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.00375	0.00815	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00365	0.00794	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00363	0.0079	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00363	0.0079	CbGpPWpGaD
Ezogabine—UGT1A3—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00345	0.0075	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.00343	0.00745	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.00343	0.00745	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00338	0.00734	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00338	0.00734	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00326	0.00708	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00304	0.0066	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00301	0.00654	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00301	0.00654	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00299	0.0065	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00271	0.00588	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00267	0.00581	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00267	0.00581	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00256	0.00556	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00256	0.00556	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00254	0.00552	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00254	0.00552	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00249	0.00541	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00245	0.00532	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00245	0.00532	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00243	0.00528	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00241	0.00524	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00239	0.00521	CbGpPWpGaD
Ezogabine—UGT1A1—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00238	0.00518	CbGpPWpGaD
Ezogabine—UGT1A9—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00238	0.00518	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.0021	0.00456	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.0021	0.00456	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00202	0.00439	CbGpPWpGaD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00201	0.00437	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.002	0.00436	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00199	0.00433	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00187	0.00407	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00187	0.00407	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00172	0.00374	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00172	0.00374	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00164	0.00356	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00162	0.00352	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00144	0.00313	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00139	0.00303	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00139	0.00303	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00138	0.00301	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00138	0.00301	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00138	0.00299	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00138	0.00299	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00113	0.00246	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00113	0.00246	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00111	0.00242	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00107	0.00234	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00107	0.00232	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00103	0.00225	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000993	0.00216	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000904	0.00197	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000861	0.00187	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.000855	0.00186	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.000837	0.00182	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000825	0.00179	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000695	0.00151	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000695	0.00151	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000685	0.00149	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000685	0.00149	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000685	0.00149	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00068	0.00148	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000674	0.00147	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000627	0.00136	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.000577	0.00125	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00057	0.00124	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00057	0.00124	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00057	0.00124	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00057	0.00124	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00056	0.00122	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000548	0.00119	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000522	0.00113	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000521	0.00113	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000455	0.00099	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00044	0.000956	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000434	0.000943	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000415	0.000903	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000412	0.000897	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000394	0.000856	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000394	0.000856	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000394	0.000856	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000394	0.000856	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000387	0.000842	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000387	0.000842	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00036	0.000783	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00036	0.000783	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000345	0.000751	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000343	0.000745	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000315	0.000684	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000315	0.000684	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000303	0.00066	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000303	0.00066	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.0003	0.000651	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.0003	0.000651	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000299	0.000649	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—EP300—attention deficit hyperactivity disorder	0.000294	0.000639	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000278	0.000603	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000243	0.000527	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000238	0.000519	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000238	0.000519	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000237	0.000515	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000237	0.000515	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000231	0.000502	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00023	0.000499	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—COMT—attention deficit hyperactivity disorder	0.000184	0.0004	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000183	0.000397	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—EP300—attention deficit hyperactivity disorder	0.000178	0.000387	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—EP300—attention deficit hyperactivity disorder	0.000148	0.000322	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—EP300—attention deficit hyperactivity disorder	0.000102	0.000222	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000102	0.000222	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—EP300—attention deficit hyperactivity disorder	7.88e-05	0.000171	CbGpPWpGaD
